The Vanguard Group - 23-1945930 13D and 13G filings for Ultragenyx Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:16 pm Purchase | 2023-12-29 | 13G | Ultragenyx Pharmaceutical Inc. RARE | The Vanguard Group - 23-1945930 | 8,673,432 10.560% | 1,436,909 (+19.86%) | Filing |
| 2023-09-11 1:33 pm Purchase | 2023-08-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | The Vanguard Group - 23-1945930 | 7,236,523 10.120% | 862,293 (+13.53%) | Filing |
| 2023-02-09 11:35 am Purchase | 2022-12-30 | 13G | Ultragenyx Pharmaceutical Inc. RARE | The Vanguard Group - 23-1945930 | 6,374,230 9.090% | 453,662 (+7.66%) | Filing |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | The Vanguard Group - 23-1945930 | 5,920,568 8.690% | 270,183 (+4.78%) | Filing |
| 2021-02-10 11:57 am Purchase | 2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | The Vanguard Group - 23-1945930 | 5,650,385 8.570% | 797,226 (+16.43%) | Filing |